SCHEMBL19461990

SCHEMBL19461990

CCCCC=CCCCCCCCCCc1cccc(O)c1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BID P55957 6/20 0.68
MCL1 Q07820 6/20 0.68
BCL2L1 Q07817 5/20 0.68
BAK1 Q16611 5/20 0.68
F7 P08709 3/20 0.64
F3 P13726 3/20 0.64
MMP2 P08253 2/20 0.64
SAE1 Q9UBE0 2/20 0.64
KDM4E B2RXH2 1/20 0.64
MAPT P10636 1/20 0.64
ALOX15 P16050 1/20 0.64
ECE1 P42892 1/20 0.64
SGMS1 Q86VZ5 1/20 0.64
SGMS2 Q8NHU3 1/20 0.64
MUS81 Q96NY9 1/20 0.64
HSD17B10 Q99714 1/20 0.64
IAPP P10997 1/20 0.54
KAT8 Q9H7Z6 2/20 0.50
PPARG P37231 1/20 0.50
PPARA Q07869 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30678306 1.00 BID (0.68) BIDMCL1BCL2L1BAK1F7
SCHEMBL19461989 1.00 BID (0.68) BIDMCL1BCL2L1BAK1F7
SCHEMBL10532605 0.97 F7 (0.68) BIDMCL1BCL2L1BAK1F7
SCHEMBL29086188 0.97 F7 (0.68) BIDMCL1BCL2L1BAK1F7
SCHEMBL30528708 0.97 F7 (0.68) BIDMCL1BCL2L1BAK1F7
SCHEMBL11694798 0.97 F7 (0.68) BIDMCL1BCL2L1BAK1F7
SCHEMBL11694803 0.97 F7 (0.68) BIDMCL1BCL2L1BAK1F7
SCHEMBL29086190 0.97 F7 (0.68) BIDMCL1BCL2L1BAK1F7
SCHEMBL22847872 0.97 F7 (0.68) BIDMCL1BCL2L1BAK1F7
SCHEMBL29086194 0.97 F7 (0.68) BIDMCL1BCL2L1BAK1F7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922525-B Curing accelerator for oxidative polymerization type unsaturated resin, printing ink and coating material DIC株式会社 2020-09-01 CN disclosed
WO-2017180769-A1 SMALL MOLECULES FOR IMMUNOGENIC TREATMENT OF CANCER CAPTEN THERAPEUTICS INC. (US) 2017-10-19 WO disclosed